Epidermal Growth Factor Gene Polymorphism in Egyptian Patients with Hepatocellular carcinoma related to Hepatitis C

Abstract

prevalent cancers worldwide. In Egypt, its incidence has been doubling due to hepatitis C viral (HCV) infection. Epidermal growth factor (EGF) plays an important role in hepatocyte regeneration and had a role in malignant transformation. Single nucleotide polymorphism (SNP) G/G genotype was associated with higher risk for HCC development. This study was done to evaluate the correlation between EGF polymorphism and HCC in patients with HCV. METHODS: Routine investigations for liver cirrhosis and HCC, also EGF genotyping were done on 2 groups; patients with HCV related cirrhosis and patients with newly diagnosed HCC on top of cirrhosis, while the control group performed EGF genotyping only. RESULTS: EGF gene polymorphism 61*G was dominant in HCC patients. The G/G owns the highest concentration when compared with A/A and A/G genotypes, with high statistical significance between studied groups as regard number and percentage (p < 0.0001). CONCLUSIONS: EGF gene polymorphism 61*G was associated with HCC risk. Moreover, the increased concentration of EGF was associated with G/G genotype.

The Link between an Epidermal Growth Factor Gene Functional Polymorphism and Hepatocellular Carcinoma in a Cohort of Hepatitis C Egyptian Patients

“…In contrast to the current investigation findings, El Sergany et al (14) discovered that in HCC Egyptian patients, the G/G genotype was the most prevalent genotype (84%) accompanied by the A/G genotype in only 10%. In cirrhotic patients (70%), the A/G genotype was the most common, while in the control group, the A/A genotype was the most common (84%).…”

“…In the HCC group, EGF levels were considerably greater than in the HCV and control groups (unpublished data). Again, these results were agreed with the studies performed by El Sergany et al (14) and Liu et al (15) who discovered that a higher EGF level in the blood was linked to a higher tumor grade, implying that EGF may promote the growth of HCCs.…”

“…The current study demonstrated that the G allele frequency among studied HCC and HCV Egyptian patients was (76.4% and 55.8% consecutively) when making a comparison to normal individuals (46.0 percent). This is in accordance with Yang et al (13) and El Sergany et al (14) , who found the 61G allele to be a potential risk for HCC and the 61A allele to be protective.…”

Association between Epidermal Growth Factor ‎‎+61A/G (rs4444903) Gene Polymorphism with ‎Risk of Hepatocellular Carcinoma in Cirrhotic ‎Hepatitis C Patients

“…In this study, EGF genotypes and alleles were not associated with HCC progression (tumor number, tumor size, portal vein thrombosis, and tumor metastasis). In addition, no correlation was found between the different alleles, BCLC staging and Child score which were agreed with Samy Kohla et al [12] and Sergany et al [13] Unfortunately, diagnosis of HCC is usually done after considerable progression of the disease, besides, current HCC therapeutic options are ineffective for most patients. So, early detection of high-risk populations is of great importance through effective screening program.…”

Epidermal Growth Factor As a biomarker for early detection of Hepatocellular Carcinoma

“…1 Liver cancer has become the greatest prevalent tumor in males and the 2nd greatest commonly carcinoma in women in Egypt during the previous two decades, with an annual risk of HCC formation of 1-4 percent when Cirrhosis caused by the hepatitis C virus (HCV) has been identified. 2 The more frequent risk indicators for HCC in Egyptian patients are persistent HBV and HCV infections, which are seen in 70-95 percent of HCC patients. 3 History, clinical exams, imaging (ultrasound, MRI, or CT scan indicating a liver tumor compatible with HCC) and possibly increased blood AFP (>400 ng/ml) are used to diagnose HCC.…”